Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599012 | 0.95 | ESR1 (0.32) | OPRD1ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL7604625 | 0.83 | GBA1 (0.33) | ESR1ESR2 | |
| SCHEMBL7598529 | 0.82 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL7598532 | 0.72 | MKNK1 (0.32) | ESR1ESR2 | |
| SCHEMBL7603945 | 0.69 | ESR1 (0.39) | OPRD1ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL7603939 | 0.69 | ESR1 (0.39) | OPRD1ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL7601542 | 0.65 | SLC6A2 (0.39) | ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL7601551 | 0.65 | SLC6A2 (0.39) | ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL7603943 | 0.60 | ESR1 (0.56) | OPRD1ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL27569312 | 0.59 | SLC6A4 (0.52) | OPRD1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | claimed |
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | ESRRB, ESR2, ESRRG | OPRD1 892/4885ESR1 6/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.